Rilpivirine: second generation NNRTI launched

A new NNRTI, rilpivirine, has been launched as both a single component tablet, Edurant, and a combination tablet with emtricitabine and tenofovir, Eviplera.

Two rilpivirine-containing products launched: Edurant is a single component tablet and Eviplera is a fixed-dose combination tablet also containing emtricitabine and tenofovir
Two rilpivirine-containing products launched: Edurant is a single component tablet and Eviplera is a fixed-dose combination tablet also containing emtricitabine and tenofovir

Edurant is indicated in combination with other antiretrovirals for treatment-naïve patients with a viral load of 100 000 HIV-1 RNA copies/ml or less. Eviplera, the fixed-dose once-daily combination tablet (rilpivirine, emtricitabine and tenofovir disoproxil), is licensed for the same indication but as monotherapy.

PHARMACOLOGY

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1.  It does not affect human cellular DNA polymerases alpha, beta or gamma. Like other second-generation diarylpyrimidine NNRTIs, it has a higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs.1,2

CLINICAL STUDIES

The efficacy and safety of rilpivirine in triple combination therapy was assessed in 2 randomised, double-blind, phase 3 non-inferiority trials using efavirenz as the comparator. In addition to rilpivirine (25mg) or efavirenz (600mg) once daily, patients enrolled in THRIVE (n=678) received tenofovir disoproxil plus emtricitabine, zidovudine plus lamivudine, or abacavir plus lamivudine; participants in ECHO (n=690) all received tenofovir disoproxil plus emtricitabine. The primary endpoint was virologic response, defined as a viral load of less than 50 HIV-1 RNA copies/ml.3,4

Response rates after 48 weeks were comparable for rilpivirine and efavirenz in both THRIVE (86% vs 82%) and ECHO (83% vs 83%), with rilpivirine meeting the criteria for non-inferiority in both cases. Rates of virologic failure were higher with rilpivirine than efavirenz (THRIVE: 7% vs 5%; ECHO: 13% vs 6%). However, there were fewer Grade 2–4 treatment-related adverse events with rilpivirine than efavirenz (16% vs 31% in both studies) and fewer discontinuations due to adverse events (THRIVE: 4% vs 7%; ECHO: 2% vs 8%).3,4

REFERENCES

1.    Edurant Summary of Product Characteristics, November 2011.
2.    Eviplera Summary of Product Characteristics, November 2011.
3.    Cohen CJ et al. Lancet 2011;378:229-37.
4.    Molina JM et al. Lancet 2011;378:238-46.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases